Hanno Roder has made pioneering contributions in defining therapeutic development approaches in Alzheimer's disease. He obtained a doctorate in organic chemistry from the University of Wuerzburg/Germany, and received post-doctoral training in Biochemistry and Neurobiology at MIT with Prof. V. Ingram and at the Marine Biological Laboratory at Woods Hole, MA. His industrial experience covers several drug discovery related positions of increasing responsibility at Bayer AG (Wuppertal/Germany) and Bayer Corp. (West Haven, CT), and was a member of various committees. In 1999 he founded NADAG, a Munich based CNS company, and built up its operations as CEO and board member until its merger. He is the principal founder and President of TauTaTis and generated its initial intellectual property base. He recently concluded a Visiting Scientist appointment at the Mayo Clinic Jacksonville, where he investigated transgenic mouse models as drug development tools in collaboration with the laboratory of Dr. Michael Hutton.
Dr. Picker has been the driving force behind several new therapeutic approaches for cancer from bench to bed side. He was the principal discoverer and developer of Carbo-platin and the family of compounds based thereon at Johnson Matthey. He oversaw the first IND for an anti-sense RNA therapeutic agent at Genta, and has since been involved with a number of entrepreneurial companies in the building of R&D teams for the clinical development new anti-cancer therapies, and successful financing of such companies.
Mr. Henry started his career with Citibank in New York as a commercial lending officer, and was subsequently responsible for all commercial and industrial loans at 42 Citibank branches as well as the National Division. Subsequently, he founded his Wall Street Investment Banking business, Henry & Co., which specialized in middle market M & A transactions and institutional research. After 10 years as an investment banker, he was Chairman, CEO and CFO of 8 medical device and health care service companies. In 1982, he founded Henry Venture Funds and over 20 years was lead institutional investor in 12 health care and biotech startups with a combined market capitalization of $ 1.5 billion. He later became Adjunct Professor of Finance at Kellogg Graduate School of Management, Northwestern University where he created and taught a highly successful course on Venture Capital. He wrote and published a course textbook entitled The Good, The Bad and The Living Dead.